Carcinoid tumor - malignant
Also known as: Fibroid, Leiomyoma, Fibrous, Tumor
Methodology & AI Transparency ⓘ
Carcinoid tumor - malignant Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code C50.0 in Cancer & Oncology, Carcinoid tumor - malignant (also termed Fibroid or Leiomyoma) requires immunohistochemistry [Carcinoid tumor - malignant C50.0] so specialists can calibrate treatment intensity against Complete Blood Count in Carcinoid tumor - malignant (C50.0: (ANC, Hemoglobin, Platelets)) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry C50.0: Carcinoid tumor - malignant is managed within Cancer & Oncology (aka Fibroid).
- 3 Typical cash cost range: Primary evaluation for Carcinoid tumor - malignant incorporates immunohistochemistry [Carcinoid tumor - malignant C50.0] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Carcinoid tumor - malignant: Complete Blood Count in Carcinoid tumor - malignant (C50.0: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (C50.0)) and Comprehensive Metabolic & in Carcinoid tumor - malignant (C50.0: Organ Function Panel).
Ask our AI Specialists anything about Carcinoid tumor - malignant
What Is Carcinoid tumor - malignant?
Cataloged under federal diagnostic code C50.0 in Cancer & Oncology, Carcinoid tumor - malignant (also termed Fibroid or Leiomyoma) requires immunohistochemistry [Carcinoid tumor - malignant C50.0] so specialists can calibrate treatment intensity against Complete Blood Count in Carcinoid tumor - malignant (C50.0: (ANC, Hemoglobin, Platelets)) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in cancer & oncology, Carcinoid tumor - malignant (C50.0) involves local tissue remodeling [Carcinoid tumor - malignant C50.0]. progression correlates with shifts in Complete Blood Count in Carcinoid tumor - malignant (C50.0: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (C50.0)).
Common Symptoms & Clinical Signs
- • Presentation of Carcinoid tumor - malignant (C50.0): persistent painless lump, in Carcinoid tumor - malignant (C50.0: non-healing ulcer/mole change,)
- • Secondary Carcinoid tumor - malignant clinical sign: unintended weight loss [Carcinoid tumor - malignant C50.0]
- • Symptom flares in Carcinoid tumor - malignant correlating with Complete Blood Count in Carcinoid tumor - malignant (C50.0: (ANC, Hemoglobin, Platelets)) deviation outside Safe hematologic reserve (C50.0)
- • Functional cancer & oncology impact requiring immunohistochemistry [Carcinoid tumor - malignant C50.0] evaluation (C50.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Carcinoid tumor - malignant Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C50.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Carcinoid tumor - malignant (C50.0: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C50.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Carcinoid tumor - malignant (C50.0: Organ Function Panel) | Preserved renal/hepatic clearance (C50.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Carcinoid tumor - malignant (C50.0: Genomic Staging) | Guideline-concordant surveillance (C50.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Carcinoid tumor - malignant
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Pafolacianine Injection Cytalux • RxCUI RXN-81052138-1785 | Optical Imaging Agent | 80% | $1.3200 | $ 61.96 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Carcinoid tumor - malignant)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Managing Sarcomatoid kidney cell carcinoma: Can Add-on treatment Make a Real Difference? (What a 171-Person Study Found) Add-on treatment with sunitinib or sorafenib did not show an improvement in DFS or OS in patients with sRCC. BJU international • 2022-06-15 • Phase III Randomized Trial | N = 171 | 88/100 | PMID 34480522 ↗ |
| Can This Approach Help? Inside the Latest Research on Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: The time of onset of sustained BM frequency improvement mean and range are important when considering use of telotristat ethyl in patients with carcinoid syndrome diarrhea. Journal of gastrointestinal cancer • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32146619 ↗ |
| Can This Approach Help? Inside the Latest Research on Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate For ARPI-naïve patients who did not receive darolutamide in ARASENS, postprogression survival was longer with subsequent ARPI versus taxane treatment, but OS remained shorter in comparison to the darolutamide group. European urology • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40544121 ↗ |
| New Insights on Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for: What a 324-Participant Study Found Grade ≥3 side effects occurred in 47.6% versus 30.7% of patients. Cancer cell • 2025-12-08 • Phase III Randomized Trial | N = 324 | 87/100 | PMID 41072417 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term risk of major cardiac events in breast cancer patients treated with Multivariate analyses confirmed that MHD (p = 0.044; hazard ratio [HR], 1.21 per 1 Gy; 95% confidence interval [CI], 1.09-1.46) and age (p = 0.034; HR, 1.07 per 1 year; 95% CI, 1.03-1.14) were significant factors of MCEs. International journal of cancer • 2025-10-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40345828 ↗ |
Carcinoid tumor - malignant Patient Community & “People Like Me” Threads
Filter Carcinoid tumor - malignant community threads and patient logs by age, biological sex, dosage, and treatment duration.